Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal
Article first published online: 12 JAN 2010
© 2011 The Authors. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland
Volume 13, Issue 5, pages 555–560, May 2011
How to Cite
Regadas, F. S. P., Pinto, R. A., Murad-Regadas, S. M., Canedo, J. A., Leal, M., Nogueras, J. J. and Wexner, S. D. (2011), Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal. Colorectal Disease, 13: 555–560. doi: 10.1111/j.1463-1318.2010.02186.x
- Issue published online: 12 JAN 2010
- Article first published online: 12 JAN 2010
- Accepted manuscript online: 4 AUG 2010 12:19PM EST
- Received 17 September 2009; accepted 26 November 2009; Accepted Article online 12 January 2010
- Immunosuppressive agents;
- ileostomy reversal;
- inflammatory bowel disease
Aim We evaluated the impact of immunosuppressive drugs on the short-term outcome following loop ileostomy closure in patients with inflammatory bowel disease.
Method Data on 249 patients with inflammatory bowel disease, who underwent loop ileostomy closure from 2001 to 2008, were retrospectively reviewed from a prospectively maintained database. Patients were distributed among groups according to the inflammatory bowel disease drugs used. Comorbidity, diagnosis, intra-operative and postoperative morbidity and length of stay data were analysed. Patients in group (INF) were receiving infliximab with or without other immunosuppressive agents (28), patients in group (S) were receiving only steroids (72) and those, in group III (S&I) were on steroids plus immunosuppressive agents, other than infliximab (35). Patients in group (ND) had not received any immunosuppressive agents for 2 months and served as the control group (114).
Results Postoperative complication rates (wound infection, hernia, obstruction, intra-abdominal abscess, leakage, enterocutaneous fistula and sepsis) occured in 4.0, 12.0, 14 and 17.0% of patients in the four groups (P > 0.05). Reoperation was needed in 3.0% (2) of patients in group S, 6.0% (2) in S&I and 3.0% (3) in C groups, and the mean hospital stay was 4.6 (± 2.1), 5.6 (± 4.6), 5.2 (± 4.7) and 5.2 (± 6) days in groups INF, S, S&I and ND, respectively. There was no mortality.
Conclusion There were no significantly increased postoperative complications after ileostomy closure in patients who received infliximab or other immunosuppressive medications compared with patients who did not.